The median progression-free survival was 11.0 months in the TPF group and 8.2 months in the PF group (hazard ratio for disease progression or death in the TPF group, 0.72; P=0.007).

Treatment with TPF resulted in a reduction in the risk of death of 27% (P=0.02),

with a median overall survival of 18.8 months, as compared with 14.5 months in the PF group.

 

There were more grade 3 or 4 events of leukopenia and neutropenia in the TPF group and more grade 3 or 4 events of thrombocytopenia, nausea, vomiting, stomatitis, and hearing loss in the PF group.

The rates of death from toxic effects were 2.3% in the TPF group and 5.5% in the PF group